Achieving innovation in early clinical trials requires partnership and expertise. Being at the heart of world leading clinical, scientific and academic research excellence means that we can bring together the right experts needed to work together. Our expertise covers the following areas:

  • Changing the patient’s role – we have expertise in working directly with patients and clinical teams to co-create solutions to change the dynamics so that patients are co-researchers contributing to new cancer medicines
  • Decision science – a multidisciplinary team that combines research expertise in data insights, analytics, digital technology and behavioural science
  • Regulatory framework – expertise in navigating the regulatory and ethical requirements for novel data science, device and technology trial designs

Who we work with

Cancer Research UK Centre for Drug Development (CDD) – We partner with CRUK CDD to support CRUK- sponsored Phase 1 clinical trials with our advanced analytics tool, REACT

Carrick Therapeutics and Emas Pharma – through this collaboration we provide our advanced analytics tool, REACT to support a Phase 1 clinical trial and receive insights for further REACT development

Manchester Experimental Cancer Medicine Team – we collaborate to deliver the PROACT trial and Technology Clinical Trials

AstraZeneca – iDecide collaboration (£11.5M) is an innovative five-year research programme between AstraZeneca and the Manchester Cancer Research Centre (which comprises the Cancer Research UK Manchester Institute, The Christie and The University of Manchester).

iMATCH (innovate Manchester Advanced Therapies Centre Hub) is a consortium to coordinate a strategy to scale-up advanced therapies for a range of debilitating conditions. Through the iDecide research programme, AstraZeneca is one of nine business partners in iMATCH and the digital ECMT provides digital science expertise to develop rapid monitoring capabilities and integration into algorithms to establish early-warning systems